CDD completes first stage of Teijin deal
UK-based Cambridge Drug Discovery says it has successfully completedstage one of its research agreement with Japan's Teijin, signed in April last year, to discover lead compounds for the treatment of metabolic disorders. Under the terms of the deal, CDD provided access to its novel target and assay development technologies, as well as its fully-automated, high-throughput screening and diverse 100,000 compound library of drug-like molecules.
CDD chief executive Mark Treherne said "we look forward to advancing into the next stage," noting that it is also "important in increasing our visibility in Japan, which is a key market for innovative drug discovery."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze